Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

Bayer discloses antiretroviral agents

April 23, 1997

Orally bioavailable cyclic HIV protease inhibitors with low potential for drug resistance

April 22, 1997

U.S. patent approval for Theratechnologies' antisense therapy

April 22, 1997

FDA clears Epivir under traditional regulations; clinical benefit confirmed

April 22, 1997

Preclinical results reveal mechanism of action and resistance profile of GEM-91

April 21, 1997

Immtech obtains exclusive rights to novel antimicrobial pharmaceutical compounds

April 17, 1997

Genesys Pharma/Novopharm Biotech agreement provides funding for antisense drug for AIDS

April 17, 1997

Retroviral protease inhibitors disclosed by DuPont Merck

April 17, 1997

HIV viral replication halted using Eukarion's antibody lipidation technology

April 16, 1997

Gilead's PMPA reduces HIV levels in clinical trials

April 14, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...